Immune Design Corp.
(NASDAQ GM: IMDZ)
Attention investors who purchased shares of Immune Design Corp. before February 21, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of Immune Design Corp. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Merck & Co., Inc. and affiliates for $5.85 per share, or approximately $300 million.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Immune Design Corp. (“Immune Design” or the “Company”) (NasdaqGM: IMDZ) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Merck & Co., Inc. and affiliates (“Merck”) (NYSE: MRK) in a transaction valued at approximately $300 million. Under the terms of the agreement, shareholders of Immune Design will receive $5.85 in cash for each share of Immune Design common stock they own.
If you own common stock of Immune Design and purchased any shares before February 21, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.